Foz do Iguaçu
Foz do Iguaçu
Foz do Iguaçu, Paraná, Brazil5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral and Topical Phytocannabinoids for Psoriasis | Chemically-Induced Disorders, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, cannabis dependence, psoriasis, psychiatric disorder, skin disorder, substance-related disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT07839455 | |
| EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) | Neurobehavioral Manifestations, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, agnosia, fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, perceptual disorders, rheumatic disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT07498023 | |
| Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression | depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT06898606 | |
| Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With Autism | Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, atrial septal defect, autism, autism spectrum disorder, intellectual disability, nervous system disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Enrolling by invitation | Not applicable | 2026-01-08 | NCT07326423 | |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 1 / Phase 2 | 2025-08-12 | NCT07091747 |